Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544
Zealand Pharma AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.70 | 9.60 | 0.10% |
| CAC 40 | 8,401.18 | 81.31 | 0.98% |
| DAX 40 | 26,569.99 | 202.75 | 0.77% |
| Dow JONES (US) | 53,559.99 | 9.45 | -0.02% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,402.36 | 182.43 | -0.71% |
| NASDAQ | 26,402.42 | 138.93 | -0.52% |
| Nikkei 225 | 65,719.18 | 686.38 | -1.03% |
| NZX 50 Index | 13,857.23 | 89.05 | 0.65% |
| S&P 500 | 7,711.76 | 19.23 | -0.25% |
| S&P/ASX 200 | 9,080.50 | 14.90 | 0.16% |
| SSE Composite Index | 3,944.46 | 7.72 | -0.20% |